Eli Lilly boasts of high demand for new diabetes drug

While early Mounjaro demand is in the ”highest end” of the drugmaker’s projections, Eli Lilly says it is fully prepared to supply the market.

Demand for Eli Lilly’s tirzepatide, a type 2 diabetes treatment branded as Mounjaro in the US and EU, is in the ”highest end” of the company’s expectations, reports Fierce Pharma.

Eli Lilly is fully prepared to meet the Mounjaro demand, the media reports citing information from a team of Morgan Stanley analysts that recently met Eli Lilly’s chief financial officer, Anat Ashkenazi.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs